ReviewDrug delivery and translational research2018
Innovative pharmaceutical approaches for the management of inner ear disorders.
Review in Drug delivery and translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- [Efficacy of intratympanic infiltration of N-acetyl cysteine in cisplatin ototoxicity].Revista medica del Instituto Mexicano del Seguro Social · 2023Trial
- Evaluation of Intratympanic Alpha-Lipoic Acid and Diltiazem as Alternatives to Dexamethasone in Noise-Induced Hearing Loss in a Murine Model.Antioxidants (Basel, Switzerland) · 2026Article
- Latest clinical evidence and strategies for endoscopic intratympanic steroid injection in the treatment of sudden sensorineural hearing loss.American journal of translational research · 2026Review
- Optimization of pharmacological interventions in the guinea pig animal model-a new approach to calculate the perilymph volume of the scala tympani.Frontiers in neuroscience · 2023Article
- Local Delivery of Therapeutics to the Cochlea Using Nanoparticles and Other Biomaterials.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Drug delivery device for the inner ear: ultra-sharp fully metallic microneedles.Drug delivery and translational research · 2021Article
- Direct Functional Protein Delivery with a Peptide into Neonatal and Adult Mammalian Inner EarMolecular therapy. Methods & clinical development · 2020Article
- Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity.Journal of clinical medicine · 2019Article
- Intracochlear administration of steroids with a catheter during human cochlear implantation: a safety and feasibility study.Drug delivery and translational research · 2018Article
- Novel drug delivery systems, devices, and fabrication methods.Drug delivery and translational research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sense of hearing is essential for permitting human beings to interact with the environment, and its dysfunctions can strongly impact on the quality of life. In this context, the cochlea plays a fundamental role in the transformation of the airborne sound waves into electrical signals, which can be processed by the brain. However, several diseases and external stimuli (e.g., noise, drugs) can damage the sensorineural structures of cochlea, inducing progressive hearing dysfunctions until deafness. In clinical practice, the current pharmacological approaches to treat cochlear diseases are based on the almost exclusive use of systemic steroids. In the last decades, the efficacy of novel therapeutic molecules has been proven, taking advantage from a better comprehension of the pathological mechanisms underlying many cochlear diseases. In addition, the feasibility of intratympanic administration of drugs also permitted to overcome the pharmacokinetic limitations of the systemic drug administration, opening new frontiers in drug delivery to cochlea. Several innovative drug delivery systems, such as in situ gelling systems or nanocarriers, were designed, and their efficacy has been proven in vitro and in vivo in cochlear models. The current review aims to describe the art of state in the cochlear drug delivery, highlighting lights and shadows and discussing the most critical aspects still pending in the field.
Indexed as
Identifiers
28462501What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.